These findings not only elucidate the pathogenic mechanism of the circEZH2/miR-133b/IGF2BP2/CREB1 axis in CRC, but also provide promising therapeutic targets for patients with CRC. Here, IGF2BP2 is linked to colorectal carcinoma.